Cullen Frost Bankers Inc. Acquires 2,485 Shares of Stryker Corporation $SYK

Cullen Frost Bankers Inc. boosted its holdings in Stryker Corporation (NYSE:SYK) by 4.1% during the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 63,721 shares of the medical technology company’s stock after acquiring an additional 2,485 shares during the quarter. Cullen Frost Bankers Inc.’s holdings in Stryker were worth $25,210,000 at the end of the most recent reporting period.

A number of other institutional investors have also added to or reduced their stakes in SYK. Vanguard Group Inc. increased its position in shares of Stryker by 1.1% during the 1st quarter. Vanguard Group Inc. now owns 33,059,964 shares of the medical technology company’s stock valued at $12,306,572,000 after purchasing an additional 361,136 shares during the last quarter. Price T Rowe Associates Inc. MD increased its position in shares of Stryker by 9.2% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 12,131,218 shares of the medical technology company’s stock valued at $4,515,847,000 after purchasing an additional 1,021,496 shares during the last quarter. Goldman Sachs Group Inc. increased its position in shares of Stryker by 13.1% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,252,895 shares of the medical technology company’s stock valued at $838,640,000 after purchasing an additional 261,058 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in shares of Stryker by 4.2% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,086,960 shares of the medical technology company’s stock valued at $776,871,000 after purchasing an additional 83,954 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in shares of Stryker by 1.5% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 2,015,374 shares of the medical technology company’s stock valued at $750,223,000 after purchasing an additional 30,329 shares during the last quarter. 77.09% of the stock is currently owned by institutional investors.

Stryker Stock Down 0.3%

Shares of NYSE:SYK opened at $379.96 on Wednesday. The stock has a fifty day simple moving average of $379.56 and a two-hundred day simple moving average of $379.10. The stock has a market capitalization of $145.26 billion, a price-to-earnings ratio of 50.33, a PEG ratio of 2.75 and a beta of 0.94. Stryker Corporation has a 12-month low of $329.16 and a 12-month high of $406.19. The company has a current ratio of 1.78, a quick ratio of 1.06 and a debt-to-equity ratio of 0.70.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 31st. The medical technology company reported $3.13 earnings per share for the quarter, topping the consensus estimate of $3.07 by $0.06. Stryker had a return on equity of 23.94% and a net margin of 12.25%.The firm had revenue of $6.02 billion during the quarter, compared to analysts’ expectations of $5.92 billion. During the same quarter in the previous year, the business earned $2.81 earnings per share. The company’s revenue was up 11.1% on a year-over-year basis. Stryker has set its FY 2025 guidance at 13.400-13.600 EPS. On average, research analysts anticipate that Stryker Corporation will post 13.47 earnings per share for the current fiscal year.

Stryker Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, October 31st. Stockholders of record on Tuesday, September 30th will be paid a $0.84 dividend. The ex-dividend date is Tuesday, September 30th. This represents a $3.36 annualized dividend and a dividend yield of 0.9%. Stryker’s payout ratio is currently 44.50%.

Insider Buying and Selling at Stryker

In other news, insider Viju Menon sold 500 shares of the business’s stock in a transaction on Monday, August 25th. The stock was sold at an average price of $390.61, for a total value of $195,305.00. Following the completion of the transaction, the insider owned 12,511 shares in the company, valued at $4,886,921.71. The trade was a 3.84% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ronda E. Stryker sold 200,000 shares of the business’s stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $376.45, for a total value of $75,290,000.00. Following the completion of the transaction, the director owned 3,222,108 shares of the company’s stock, valued at $1,212,962,556.60. This represents a 5.84% decrease in their position. The disclosure for this sale can be found here. 5.20% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

SYK has been the topic of several recent research reports. UBS Group set a $408.00 price objective on Stryker in a research report on Monday, October 13th. Weiss Ratings restated a “buy (b-)” rating on shares of Stryker in a research report on Wednesday, October 8th. BTIG Research lifted their price objective on Stryker from $407.00 to $408.00 and gave the stock a “buy” rating in a research report on Monday, October 13th. Wall Street Zen upgraded Stryker from a “hold” rating to a “buy” rating in a research report on Saturday. Finally, Rothschild & Co Redburn assumed coverage on Stryker in a research note on Thursday, September 18th. They issued a “neutral” rating and a $420.00 target price for the company. Fifteen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, Stryker currently has an average rating of “Moderate Buy” and a consensus price target of $431.76.

Stryker Company Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.